Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linvoseltamab + carfilzomib
- Development stage
- Phase 3
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Linvoseltamab + carfilzomib is a combination therapy investigated for treatment of relapsed/refractory multiple myeloma, particularly in patients with prior exposure to multiple drug classes. Linvoseltamab (REGN5458, marketed as Lynozyfic) is a BCMA × CD3 bispecific monoclonal antibody that redirects cytotoxic T cells to multiple myeloma cells expressing B-cell maturation antigen (BCMA), thereby promoting T-cell–mediated tumor cell lysis. Carfilzomib (brand name Kyprolis, code name PR-171) is a second-generation, irreversible proteasome inhibitor that selectively inhibits the chymotrypsin-like activity of the 20S proteasome, leading to apoptosis and growth inhibition of malignant plasma cells. The combination aims for synergistic cytoreduction by enhancing both immunostimulatory and cytotoxic mechanisms, with early clinical data indicating robust response rates and manageable toxicity profiles in heavily pretreated populations[1][4][2][3][5].
- Other names
- linvoseltamab + carfilzomiblinvoseltamab-gcpt + carfilzomib
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on linvoseltamab + carfilzomib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linvoseltamab + carfilzomib.